Absci (ABSI) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Absci (ABSI) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 153.4% versus a loss of 26.2%. Over five years, ABSI leads with a -4.4% price change compared with -77.1% for RXRX. Recursion Pharmaceuticals is the larger company by market cap ($2.34 billion vs $1.74 billion), about 1.3 times the size.
Recursion Pharmaceuticals converts more of its revenue into profit, with a net margin of -863.4% versus -4113.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | RXRX |
|---|---|---|
| Share price | $10.16 | $4.36 |
| Market cap | $1.74B | $2.34B |
| 1-day change | +13.65% | +10.38% |
| YTD return | +191.12% | +6.60% |
| 1-year return | +153.37% | -26.23% |
| 5-year return | -4.42% | -77.10% |
| EPS (TTM) | $-0.79 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $74.68M |
| Revenue growth (YoY) | -38.24% | +26.92% |
| Net income (latest FY) | $-115.18M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | -4297.04% | -867.87% |
| Net margin | -4113.68% | -863.35% |
| 52-week high | $12.06 | $7.18 |
| 52-week low | $2.24 | $2.77 |
| Distance from 52-week high | -15.72% | -39.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +41.73% | +65.60% |
| Average volume | 3.43M | 20.70M |
| Shares outstanding | 171.61M | 535.34M |
| Employees | 140 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed RXRX by 179.6 percentage points over the past year.
- Recursion Pharmaceuticals is more profitable, keeping -863.4 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
- Recursion Pharmaceuticals grew revenue faster in its latest fiscal year (+26.92% vs -38.24%).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
ABSI vs RXRX FAQ
Which is bigger, Absci or Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.34B compared with $1.74B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or RXRX?
ABSI returned +153.37% over the past 12 months, compared with -26.23% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.